Dr. Suwon Kim is an Associate Professor at the University of Arizona College of Medicine-Phoenix and the Translational Genomics Research Institute. Dr. Kim obtained her undergraduate degree from University of California Berkeley and her PhD from Yale University School of Medicine. She completed her postdoctoral research in the laboratory of Dr. J. Michael Bishop at University of California San Francisco.
Dr. Kim’s research focuses on oncogenes and tumor suppressors that play a role in the emergence and therapy-resistant recurrence of breast cancer. One of her main projects is to characterize the ING4 tumor suppressor related to its functions in chromatin remodeling, transcriptional regulation, and tumor immune microenvironment modulation.
Hendricks WPD, Briones N, Halperin RE, Facista S, Heaton PR, Mahadevan D, and Kim S. (2019) PD-1-associated gene expression signature of neoadjuvant trastuzumab-treated tumors correlates with patient survival in HER2-positive breast cancer Cancers, 2019.
Keenen MM and Kim S. (2016) Tumor suppressor ING4 inhibits estrogen receptor activity in breast cancer cells. Breast Cancer (Dove Med Press) 8:211-221. PMID: 27895513 Kim S. (2015) New and emerging factors in tumorigenesis: an overview. Cancer Manag Res. , 2016.
Byron SA, Min E, Thal TS, Tapia C, Hostetter G, Watanabe A, Azorsa D, Little TH and Kim S. (2012) Attenuation of NF-kappa B by the ING4 tumor suppressor in breast cancer. PLoS One 7(10):e46823., 2012.
Tapia C, Zlobec I, Schneider S, Kilic E, Guth U, Bubendorf L and Kim S. (2011) Deletion of the ING4 tumor suppressor gene is prevalent in HER2-positive breast cancer. Human Pathology 42(7): 983-90., 2011.
Kim S, Welm AL and Bishop JM. (2010). A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis. Cancer Res 70:5155-5162., 2010.